First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults
Title:
First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naïve adults
Author:
Hutter, Jack N Robben, Paul M. Lee, Christine Hamer, Melinda Moon, James E. Merino, Kristen Zhu, Lei Galli, Heather Quinn, Xiaofei Brown, Dallas R. Duncan, Elizabeth Bolton, Jessica Zou, Xiaoyan Angov, Evelina Lanar, David E. Rao, Mangala Matyas, Gary R. Beck, Zoltan Bergmann-Leitner, Elke Soisson, Lorraine A. Waters, Norman C. Ngauy, Viseth Regules, Jason Dutta, Sheetij